Further to the announcement on 2 January 2025 (the "2.4 Announcement”) and the update on the potential combination of Poolbeg ...

In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.10% of ...

Taboola.com (TBLA) reported impressive third-quarter results with solid revenue growth of over 20%. Aspects like solid demand for its innovative services and the ability to stay ahead with the latest ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

According to Benzinga Pro, Gilead Sciences's peer group average for short interest as a percentage of float is 5.13%, which ...

RBC Capital analyst Brian Abrahams lowered the firm’s price target on Gilead (GILD) to $83 from $84 and keeps a Sector Perform rating on the ...

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global ...